118-60-5

Basic information

• Product Name: 2-Ethylhexyl salicylate
• Synonyms: 2-hydroxy-benzoicaci2-ethylhexylester;Benzoic acid, 2-hydroxy-, 2-ethylhexyl ester;Benzoicacid,2-hydroxy-,2-ethylhexylester;Dermoblock OS;Escalol 587;Ethylhexyl salicylate;Neo Heliopan OS;piedmonti,2-ethvlhexvlsavlate
• CAS NO: 118-60-5
• Molecular Formula: C₁₅H₂₂O₃
• Molecular Weight: 250.33
• EINECS: 204-263-4
• Product Categories: cosmetic raw material;UV-Absorber
• Mol File: 118-60-5.mol

Chemical Properties

• Boiling Point: 189-190 °C21 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: liquid
• Density: 1.014 g/mL at 25 °C(lit.)
• Vapor Pressure: 8.07E-05mmHg at 25°C
• Refractive Index: n20/D 1.502(lit.)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• PKA: 8.13±0.30(Predicted)
• Water Solubility: 74.4μg/L at 20℃
• Merck: 14,6770
• BRN: 2730664
• CAS DataBase Reference: 2-Ethylhexyl salicylate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Ethylhexyl salicylate(118-60-5)
• EPA Substance Registry System: 2-Ethylhexyl salicylate(118-60-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• RTECS: VO3150000
• Hazardous Substances Data: 118-60-5(Hazardous Substances Data)

Usage

Chemical Properties

liquid

Occurrence

Has apparently not been reported to occur in nature.

Uses

Different sources of media describe the Uses of 118-60-5 differently. You can refer to the following data:
1. Solvent for solid sunscreens.
2. 2-ethylhexyl salicylate is also known as ethylhexyl salicylate and octyl salicylate. It is a uVB absorber.
3. ethylhexyl salicylate is an FDA-approved uVB sunscreen chemical, it absorbs within the entire uVB range. It has an approved usage level of 3 to 5 percent in both the united States and the european union, and is a good solubilizer for benzophenone-3. In suntan lotions, it is used as a preservative and anti-microbial. This is a salt of salicylic acid occurring in wintergreen leaves and in other plants. It is also synthetically manufactured. It is considered a non-comedogenic raw material. This is the InCI name for octyl salicylate.
4. octisalate is a uVB protector. This is the drug name for ethylhexyl salicylate and octyl salicylate.

Preparation

From 2-ethylhexanol and salicylic acid by azeotropic-type esterification (Arctander, 1969).

Brand name

Escalol (ISP Van Dyk); Neo Heliopan (Haarmann & Reimer, Germany); Uvinul (BASF). Note—The International Cosmetic Ingredient (INCI) name for octisalate is octyl salicylate.

General Description

2-Ethylhexyl salicylate(EHS) is an organic ultraviolet(UV) absorber that can be used as a photostable ingredient in cosmetic formulations. It shows an absorption spectra in the range of 280-320 nm in the UV region.

Flammability and Explosibility

Nonflammable

InChI:InChI=1/C15H22O3/c1-3-5-8-12(4-2)11-18-15(17)13-9-6-7-10-14(13)16/h6-7,9-10,12,16H,3-5,8,11H2,1-2H3/t12-/m0/s1

Synthetic route

2-Ethylhexyl alcohol (104-76-7) + salicylic acid (69-72-7) → 2-ethylhexyl salicylate (118-60-5)

Conditions	Yield
With toluene-4-sulfonic acid In 5,5-dimethyl-1,3-cyclohexadiene at 150℃; Temperature; Flow reactor; High pressure; Green chemistry;	96%
With sulfuric acid unter Entfernen des entstehenden Wassers;
With sulfuric acid In toluene for 12h; Dean-Stark; Reflux;
With sodium hydrogen sulfate In n-heptane at 108.5℃; Solvent; Temperature;	99.76 %Chromat.

6,7-dimethoxy-4-chloroquinoline (35654-56-9) + 2-ethylhexyl salicylate (118-60-5) → 2-Ethylhexyl 2-[(6,7-dimethoxy-4-quinolyl)oxy]benzoate

Conditions	Yield
With dmap In 1,2-dichloro-benzene at 120 - 140℃;	18%

2-ethylhexyl salicylate (118-60-5) → trans-2-hydroxycyclohexanecarboxylic acid 2-ethylhexyl ester + cis-2-hydroxycyclohexanecarboxylic acid 2-ethylhexyl ester

Conditions	Yield
With 5% rhodium-on-charcoal; hydrogen In water; isopropyl alcohol at 65℃; under 3750.38 Torr;	A n/a B n/a

Upstream product

• 104-76-7 2-Ethylhexyl alcohol 
• 69-72-7 salicylic acid 

Related news

Determination of metabolites of the UV filter 2-Ethylhexyl salicylate (cas 118-60-5) in human urine by online-SPE-LC-MS/MS08/27/2019

The UV filter 2‑ethylhexyl salicylate (EHS) is widely used in sunscreens and other personal care products (PCP). EHS has been detected in a variety of environmental matrices. However, data on the internal EHS exposure in humans is not available, due to the lack of exposure biomarkers and analyti...detailed

Urinary metabolites of the UV filter 2-Ethylhexyl salicylate (cas 118-60-5) as biomarkers of exposure in humans08/26/2019

The UV filter 2-ethylhexyl salicylate (EHS) is used in sunscreens and other personal care products worldwide and has been found in a variety of environmental media. We aimed to provide human toxicokinetic data on EHS as a tool for risk assessment. For that purpose, we investigated metabolism and...detailed

Relevant articles and documents

Method for continuously synthesizing isooctyl salicylate in microchannel (by machine translation)

To the method, salicylic acid and isooctanol are used as a raw material to synthesize the. isooctyl salicylate to the synthesis of isooctyl salicylate in, the microchannel for a short, time in the process of flowing. (by machine translation)

SKIN WHITENING AGENT CONTAINING NOVEL CYCLIC COMPOUND

Provided is a derivative or a polyhydroxy cyclic compound represented by Formula I or a pharmacologically acceptable salt thereof with excellent whitening effects, comprising; wherein {circle around (A)} is derived from an aromatic cyclic compound, B is hydrogen, oxo (═O), amino (—NH2), imino (═NH), or a saturated or unsaturated straight or branched alkyl, alkoxy, monoalkylamino, or dialkylamino group having 1 to 10 carbon atoms, Cn, Cn+1and Cn+2 are three neighboring carbon atoms present in the aromatic cyclic compound, wherein n is a positive integer, R1 is hydrogen, hydroxy, or a saturated or unsaturated straight or branched alkyl or alkoxy group, X and Y are selected from a group consisting of hydrogen, hydroxy, and a saturated or unsaturated straight or branched alkoxy, or acyloxy group, and one of X and Y is hydrogen, R2, R3, R4 and R5 are each independently at least one substituent selected from a group consisting of hydrogen, alkyl, alkoxy, acyloxy, acyloxymethyl, oxo, hydroxy, vinyl, nitrile, carboxaldehyde, carbonitrile and aldehyde.

A method for production of salicylic acid isooctyl

The invention provides a method for industrially producing ethylhexyl salicylate. The method comprises the steps of esterifying salicylic acid and isooctyl alcohol in an n-heptane solvent under sodium hydrogen sulfate serving as a catalyst to synthesize a coarse ethylhexyl salicylate product, and enabling the salicylic acid conversion rate to be greater than or equal to 99 percent and the isooctyl ether generation amount to be less than 1 percent by controlling the backflow temperature to be 110+/-5 DEG C and the backflow water division time to be 8-10 hours; then performing decompression rectification, effectively separating impurities with different boiling points by controlling the temperature of circulating water of a built-in backflow condenser to obtain a high-purity ethylhexyl salicylate product, wherein the product yield is greater than or equal to 95 percent, and the purity of a product detected by GC (gas chromatography) is greater than or equal to 99.5 percent. The esterifying synthesized catalyst and the non-reacted salicylic acid can be both recycled and directly used for synthesis of the next batch, so that raw materials are saved and the cost are reduced. The synthesis method is reasonable in design, easy to operate and suitable for being popularized and industrialized.

PROCESS FOR TREATING SOL-GEL CAPSULES

The present invention relates to a process for treating sol-gel capsules comprising a cosmetic or pharmaceutical active material with an inorganic material, as well as sol-gel capsules produced by a process according to the present invention and formulations comprising such sol-gel capsules.

Flavonoid derivative

The invention relates to a novel flavonoid derivative, to an extract comprising the flavonoid derivative, to the cosmetic and pharmaceutical use thereof, to preparations comprising the flavonoid derivative or extract, and to a process for the preparation of the flavonoid derivative or extract.

Use of ectoin or ectoin derivatives for protecting stress proteins in the skin

The present invention relates to the use of at least one compound selected from the group comprising compounds of formulas 1a and 1b physiologically acceptable salts thereof, and stereoisomeric forms thereof, in which R1 denotes H oder alkyl, R2 denotes H, COOH, COO-alkyl or CO—NH—R5, R3 and R4 each independently denote H or OH, n is 1, 2 or 3, R5 denotes H, alkyl, an amino acid group, a dipeptide residue or a tripeptide residue, and alkyl denotes an alky group containing from 1 to 4 carbons, for protection of stress proteins in the skin. These compounds are used in the present invention in the form of a topical composition.

Use of aryl oximes for the prophylaxis and/or treatment of erythema formation and/or inflammatory reaction of the skin

The present invention relates to the use of at least one aryl oxime of Formula (I). wherein: Y, Z represent independently from each other H, C1-18 alkyl, C2-18 alkenyl, C2-18 carboxy alkyl, C3-18 carboxy alkenyl or C2-18 alkanoyl; R represents C1-18 alkyl, C2-18 alkenyl, C3-8 cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or condensed systems; R1, R2, R3 and R4 represent independently from each other H, C1-12 alkyl, C2-12 alkenyl, C1-12 alkoxy, C3-8 cycloalkoxy, aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, carboxy, hydroxy, chlorine, dialkyl amine or sulfonyl, for the prophylaxis and/or treatment of erythema formation and/or inflammation responses of the skin.

Topical composition containing at least one aryl oxime, and method for the preparation thereof

The present invention relates to a topical composition, comprising (c) at least one aryl oxime of the Formula (I) and (d) at least one emulsifier, wherein: Y, Z represent independently from each other H, C1-18 alkyl, C2-18 alkenyl, C2-18 carboxy alkyl, C3-18 carboxy alkenyl or C2-18 alkanoyl; R represents C1-18 alkyl, C2-18 alkenyl, C3-8 cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or condensed systems; R1, R2, R3 and R4 represent independently from each other H, C1-12 alkyl, C2-12 alkenyl, C1-12 alkoxy, C3-8 cycloalkoxy, aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, carboxy, hydroxy, chlorine, dialkyl amine or sulfonyl, wherein the component (b) is selected from the group consisting of an ester, the carboxylic acid residue of which is derived from C5-C16 acids and the hydroxyl residue of which is derived from monomers, dimers or trimers of lactic acid or one of its salts or a polyglycerin of 2 to 10 molecules of glycerin whereby 1 to 3 moles of carboxylic acid are present per mole of polyglycerin. Furthermore, the present invention relates to a process for the preparation of said topical composition as well as the use of said topical composition.

Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof

The present invention relates to a composition, comprising (a) at least one aryl oxime of Formula (I) and (b) at least one active agent for the treatment of acne ?wherein: Y, Z represent independently from each other H, C1-18 alkyl, C2-18 alkenyl, C2-18 carboxy alkyl, C3-18 carboxy alkenyl or C2-18 alkanoyl; R represents C1-18 alkyl, C2-18 alkenyl, C3-8 cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or condensed systems; R1, R2, R3 and R4 represent independently from each other H, C1-12 alkyl, C2-12 alkenyl, C1-12 alkoxy, C3-8 cycloalkoxy, aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, carboxy, hydroxy, chlorine, dialkyl amine or sulfonyl. Moreover, the present invention relates to the use of this composition as well as the use of the aforementioned aryl oxime of Formula (I).

Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression

The present invention relates to the use of at least one compound selected from the group comprising compounds of formulas 1a and 1b physiologically acceptable salts thereof and stereoisomeric forms thereof, in which R1 denotes H oder alkyl, R2 denotes H, COOH, COO-alkyl or CO—NH—R5, R3 and R4 each independently denote H or OH, n is 1, 2 or 3, R5 denotes H, alkyl, an amino acid group, a dipeptide residue or a tripeptide residue, and alkyl denotes an alkyl group containing from 1 to 4 carbons, for the prophylaxis and/or treatment of immunosuppression. These compounds are used in the present invention in the form of a topical composition.